Regeneron Pharmaceuticals (REGN)

• Market cap: $64.2B
• 1 day: 0.11%
• 5 days: -4.06%
• 1 month: -15.38%
• 3 months: -18.01%
• 6 months: -17.42%
• Year to date: -21.15%
• 1 year: 17.3%
• 5 years: 15.77%
• 10 years: 66.69%
• Sector: Healthcare
• Industry: Biotechnology

About: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Employees: 15,410